Applications of CRISPR technology in cellular immunotherapy

Base editing screens map mutations affecting interferon-γ signaling in cancer

(2023) Matthew A. Coelho et al.   CANCER CELL

A transcription factor atlas of directed differentiation

(2023) Julia Joung et al.   CELL

Massively parallel knock-in engineering of human T cells

(2023) Xiaoyun Dai et al.   NATURE BIOTECHNOLOGY

Predicting prime editing efficiency and product purity by deep learning

(2023) Nicolas Mathis et al.   NATURE BIOTECHNOLOGY

Deletion of SNX9 alleviates CD8 T cell exhaustion for effective cellular cancer immunotherapy

(2023) Marcel P. Trefny et al.   Nature Communications

Human T cell generation is restored in CD3δ severe combined immunodeficiency through adenine base editing

(2023) Grace E. McAuley et al.   CELL

Neoantigen-targeted CD8+ T cell responses with PD-1 blockade therapy

(2023) Cristina Puig-Saus et al.   NATURE

Efficient engineering of human and mouse primary cells using peptide-assisted genome editing

(2023) Zhen Zhang et al.   NATURE BIOTECHNOLOGY

Stable expression of large transgenes via the knock-in of an integrase-deficient lentivirus

(2023) Michael Chavez et al.   Nature Biomedical Engineering

Peptide-mediated delivery of CRISPR enzymes for the efficient editing of primary human lymphocytes

(2023) Dana V. Foss et al.   Nature Biomedical Engineering

CRISPR activation and interference screens decode stimulation responses in primary human T cells

(2022) Ralf Schmidt et al.   SCIENCE

CAR T cells produced in vivo to treat cardiac injury

(2022) Joel G. Rurik et al.   SCIENCE

CRISPR-based gene disruption and integration of high-avidity, WT1-specific T cell receptors improve antitumor T cell function

(2022) Eliana Ruggiero et al.   Science Translational Medicine

CRISPR/Cas9 genome-edited universal CAR T cells in patients with relapsed and refractory lymphoma

(2022) Yelei Guo et al.   Blood Advances

Cytosine Base Editing Enables Quadruple-Edited Allogeneic CAR-T Cells for T-ALL

(2022) Caroline Diorio et al.   BLOOD

A genome-scale gain-of-function CRISPR screen in CD8 T cells identifies proline metabolism as a means to enhance CAR-T therapy

(2022) Lupeng Ye et al.   Cell Metabolism

High-efficiency nonviral CRISPR/Cas9-mediated gene editing of human T cells using plasmid donor DNA

(2022) Soyoung A. Oh et al.   JOURNAL OF EXPERIMENTAL MEDICINE

CAR T cell killing requires the IFNγR pathway in solid but not liquid tumours

(2022) Rebecca C. Larson et al.   NATURE

A genome-scale screen for synthetic drivers of T cell proliferation

(2022) Mateusz Legut et al.   NATURE

Enhancing CRISPR/Cas gene editing through modulating cellular mechanical properties for cancer therapy

(2022) Di Zhang et al.   Nature Nanotechnology

Emerging NK cell therapies for cancer and the promise of next generation engineering of iPSC-derived NK cells

(2022) Sainiteesh Maddineni et al.   Journal for ImmunoTherapy of Cancer

Genome-wide CRISPR screens of T cell exhaustion identify chromatin remodeling factors that limit T cell persistence

(2022) Julia A. Belk et al.   CANCER CELL

Universal allogeneic CAR T cells engineered with Sleeping Beauty transposons and CRISPR-CAS9 for cancer immunotherapy

(2022) Jaitip Tipanee et al.   MOLECULAR THERAPY

The Past, Present, and Future of Non-Viral CAR T Cells

(2022) Alex Moretti et al.   Frontiers in Immunology

Non-viral, specifically targeted CAR-T cells achieve high safety and efficacy in B-NHL

(2022) Jiqin Zhang et al.   NATURE

Phase 1 clinical trial of CRISPR-engineered CAR19 universal T cells for treatment of children with refractory B cell leukemia

(2022) Giorgio Ottaviano et al.   Science Translational Medicine

CTX110 Allogeneic CRISPR-Cas9-Engineered CAR T Cells in Patients (Pts) with Relapsed or Refractory (R/R) Large B-Cell Lymphoma (LBCL): Results from the Phase 1 Dose Escalation Carbon Study

(2022) Joseph P. McGuirk et al.   BLOOD

A First-in-Human Phase 1, Multicenter, Open-Label Study of CB-010, a Next-Generation CRISPR-Edited Allogeneic Anti-CD19 CAR-T Cell Therapy with a PD-1 Knockout, in Patients with Relapsed/Refractory B Cell Non-Hodgkin Lymphoma (ANTLER Study)

(2022) Susan O'Brien et al.   BLOOD

Double knockout CRISPR screen for cancer resistance to T cell cytotoxicity

(2022) Jonathan J. Park et al.   Journal of Hematology & Oncology

Non-viral precision T cell receptor replacement for personalized cell therapy

(2022) Susan P. Foy et al.   NATURE

Enhanced T cell effector activity by targeting the Mediator kinase module

(2022) Katherine A. Freitas et al.   SCIENCE

Simultaneous editing of TCR, HLA-I/II and HLA-E resulted in enhanced universal CAR-T resistance to allo-rejection

(2022) Wuling Li et al.   Frontiers in Immunology

In Vivo T Cell-Targeting Nanoparticle Drug Delivery Systems: Considerations for Rational Design

(2021) Paula M. Cevaal et al.   ACS Nano

In vivo CRISPR screening reveals nutrient signaling processes underpinning CD8+ T cell fate decisions

(2021) Hongling Huang et al.   CELL

In vivo CD8+ T cell CRISPR screening reveals control by Fli1 in infection and cancer

(2021) Zeyu Chen et al.   CELL

CRISPR/Cas9-engineered universal CD19/CD22 dual-targeted CAR-T cell therapy for relapsed/refractory B-cell acute lymphoblastic leukemia

(2021) Yongxian Hu et al.   CLINICAL CANCER RESEARCH

Cas9-directed immune tolerance in humans—a model to evaluate regulatory T cells in gene therapy?

(2021) Dimitrios Laurin Wagner et al.   GENE THERAPY

Multimodal pooled Perturb-CITE-seq screens in patient models define mechanisms of cancer immune evasion

(2021) Chris J. Frangieh et al.   NATURE GENETICS

Applications of CRISPR Genome Editing to Advance the Next Generation of Adoptive Cell Therapies for Cancer

(2021) Samantha M. Fix et al.   Cancer Discovery

The Natural Killer–Dendritic Cell Immune Axis in Anti-Cancer Immunity and Immunotherapy

(2021) Erin E. Peterson et al.   Frontiers in Immunology

Phase I study of CAR-T cells with PD-1 and TCR disruption in mesothelin-positive solid tumors

(2021) Zhenguang Wang et al.   Cellular & Molecular Immunology

Prime editing – an update on the field

(2021) Janine Scholefield et al.   GENE THERAPY

CRISPR/Cas9 mediated deletion of the adenosine A2A receptor enhances CAR T cell efficacy

(2021) Lauren Giuffrida et al.   Nature Communications

Genetic ablation of PRDM1 in antitumor T cells enhances therapeutic efficacy of adoptive immunotherapy

(2021) Toshiaki Yoshikawa et al.   BLOOD

Clinical-Scale Production and Characterization of Ntla-5001 - a Novel Approach to Manufacturing CRISPR/Cas9 Engineered T Cell Therapies

(2021) Daniel Cossette et al.   BLOOD

First-in-Human Assessment of Feasibility and Safety of Multiplexed Genetic Engineering of Autologous T Cells Expressing NY-ESO -1 TCR and CRISPR/Cas9 Gene Edited to Eliminate Endogenous TCR and PD-1 (NYCE T cells) in Advanced Multiple Myeloma (MM) and Sarcoma

(2020) Edward A. Stadtmauer et al.   BLOOD

NK cells for cancer immunotherapy

(2020) Noriko Shimasaki et al.   NATURE REVIEWS DRUG DISCOVERY

CRISPR-engineered T cells in patients with refractory cancer

(2020) Edward A. Stadtmauer et al.   SCIENCE

Genetic screens in isogenic mammalian cell lines without single cell cloning

(2020) Peter C. DeWeirdt et al.   Nature Communications

Unleashing Natural Killer Cells in the Tumor Microenvironment–The Next Generation of Immunotherapy?

(2020) Aviad Ben-Shmuel et al.   Frontiers in Immunology

Pooled Knockin Targeting for Genome Engineering of Cellular Immunotherapies

(2020) Theodore L. Roth et al.   CELL

CRISPR screen in regulatory T cells reveals modulators of Foxp3

(2020) Jessica T. Cortez et al.   NATURE

Safety and feasibility of CRISPR-edited T cells in patients with refractory non-small-cell lung cancer

(2020) You Lu et al.   NATURE MEDICINE

Selective organ targeting (SORT) nanoparticles for tissue-specific mRNA delivery and CRISPR–Cas gene editing

(2020) Qiang Cheng et al.   Nature Nanotechnology

Genetic Ablation of HLA Class I, Class II, and the T-cell Receptor Enables Allogeneic T Cells to Be Used for Adoptive T-cell Therapy

(2020) Yuki Kagoya et al.   Cancer Immunology Research

Lipid nanoparticles for nucleic acid delivery: Current perspectives

(2020) Eleni Samaridou et al.   ADVANCED DRUG DELIVERY REVIEWS

Endogenous TCR promotes in vivo persistence of CD19-CAR-T cells compared to a CRISPR/Cas9-mediated TCR knockout CAR

(2020) Dana Stenger et al.   BLOOD

Multi-phenotype CRISPR-Cas9 Screen Identifies p38 Kinase as a Target for Adoptive Immunotherapies

(2020) Devikala Gurusamy et al.   CANCER CELL

Detection and Modulation of DNA Translocations During Multi-Gene Genome Editing in T Cells

(2020) Anne Bothmer et al.   CRISPR Journal

An efficient KRAB domain for CRISPRi applications in human cells

(2020) Nader Alerasool et al.   NATURE METHODS

CRISPR-GEMM pooled mutagenic screening identifies KMT2D as a major modulator of immune checkpoint blockade

(2020) Guangchuan Wang et al.   Cancer Discovery

A web tool for the design of prime-editing guide RNAs

(2020) Ryan D. Chow et al.   Nature Biomedical Engineering

Convergent Identification and Interrogation of Tumor-Intrinsic Factors that Modulate Cancer Immunity In Vivo

(2019) Adan Codina et al.   Cell Systems

One-step generation of modular CAR-T cells with AAV–Cpf1

(2019) Xiaoyun Dai et al.   NATURE METHODS

JACKS: joint analysis of CRISPR/Cas9 knockout screens

(2019) Felicity Allen et al.   GENOME RESEARCH

In vivo profiling of metastatic double knockouts through CRISPR–Cpf1 screens

(2019) Ryan D. Chow et al.   NATURE METHODS

The next generation of CRISPR–Cas technologies and applications

(2019) Adrian Pickar-Oliver et al.   NATURE REVIEWS MOLECULAR CELL BIOLOGY

Multifunctional CRISPR-Cas9 with engineered immunosilenced human T cell epitopes

(2019) Shayesteh R. Ferdosi et al.   Nature Communications

Systematic Immunotherapy Target Discovery Using Genome-Scale In Vivo CRISPR Screens in CD8 T Cells

(2019) Matthew B. Dong et al.   CELL

In vivo CRISPR screening in CD8 T cells with AAV–Sleeping Beauty hybrid vectors identifies membrane targets for improving immunotherapy for glioblastoma

(2019) Lupeng Ye et al.   NATURE BIOTECHNOLOGY

Search-and-replace genome editing without double-strand breaks or donor DNA

(2019) Andrew V. Anzalone et al.   NATURE

Multiplexed activation of endogenous genes by CRISPRa elicits potent antitumor immunity

(2019) Guangchuan Wang et al.   NATURE IMMUNOLOGY

High levels of AAV vector integration into CRISPR-induced DNA breaks

(2019) Killian S. Hanlon et al.   Nature Communications

Highly efficient multiplex human T cell engineering without double-strand breaks using Cas9 base editors

(2019) Beau R. Webber et al.   Nature Communications

CRISPR-Cas9 disruption of PD-1 enhances activity of universal EGFRvIII CAR T cells in a preclinical model of human glioblastoma

(2019) Bryan D. Choi et al.   Journal for ImmunoTherapy of Cancer

Targeting REGNASE-1 programs long-lived effector T cells for cancer therapy

(2019) Jun Wei et al.   NATURE

Polymer-stabilized Cas9 nanoparticles and modified repair templates increase genome editing efficiency

(2019) David N. Nguyen et al.   NATURE BIOTECHNOLOGY

Evolutionary classification of CRISPR–Cas systems: a burst of class 2 and derived variants

(2019) Kira S. Makarova et al.   NATURE REVIEWS MICROBIOLOGY

P-130A phase I/II Trial of CRISPR-Cas9-mediated PD-1 knockout Epstein-Barr virus cytotoxic lymphocytes (EBV-CTLs) for advanced stage EBV associated malignancies - Trial in progress

(2018) J Wei et al.   ANNALS OF ONCOLOGY

Optimized DNA electroporation for primary human T cell engineering

(2018) Zhang Zhang et al.   BMC BIOTECHNOLOGY

CRISPR/Cas9-mediated knockout of DGK improves anti-tumor activities of human T cells

(2018) In-Young Jung et al.   CANCER RESEARCH

Repair of double-strand breaks induced by CRISPR–Cas9 leads to large deletions and complex rearrangements

(2018) Michael Kosicki et al.   NATURE BIOTECHNOLOGY

Improving cytidine and adenine base editors by expression optimization and ancestral reconstruction

(2018) Luke W Koblan et al.   NATURE BIOTECHNOLOGY

Enhancing T cell therapy through TCR-signaling-responsive nanoparticle drug delivery

(2018) Li Tang et al.   NATURE BIOTECHNOLOGY

In vivo simultaneous transcriptional activation of multiple genes in the brain using CRISPR–dCas9-activator transgenic mice

(2018) Haibo Zhou et al.   NATURE NEUROSCIENCE

Genome-wide CRISPR screen identifies FAM49B as a key regulator of actin dynamics and T cell activation

(2018) Wanjing Shang et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

CAR T cell immunotherapy for human cancer

(2018) Carl H. June et al.   SCIENCE

Programmable sequential mutagenesis by inducible Cpf1 crRNA array inversion

(2018) Ryan D. Chow et al.   Nature Communications

Emerging Issues in AAV-Mediated In Vivo Gene Therapy

(2018) Pasqualina Colella et al.   Molecular Therapy-Methods & Clinical Development

Large deletions induced by Cas9 cleavage

(2018) Fatwa Adikusuma et al.   NATURE

Reprogramming human T cell function and specificity with non-viral genome targeting

(2018) Theodore L. Roth et al.   NATURE

CRISPR-Cas guides the future of genetic engineering

(2018) Gavin J. Knott et al.   SCIENCE

Genome-wide CRISPR Screens in Primary Human T Cells Reveal Key Regulators of Immune Function

(2018) Eric Shifrut et al.   CELL

Coupled Single-Cell CRISPR Screening and Epigenomic Profiling Reveals Causal Gene Regulatory Networks

(2018) Adam J. Rubin et al.   CELL

Optimized libraries for CRISPR-Cas9 genetic screens with multiple modalities

(2018) Kendall R. Sanson et al.   Nature Communications

CRISPR knock out CTLA-4 enhances the anti-tumor activity of cytotoxic T lymphocytes

(2017) Long Shi et al.   GENE

Cocktail treatment with EGFR-specific and CD133-specific chimeric antigen receptor-modified T cells in a patient with advanced cholangiocarcinoma

(2017) Kai-chao Feng et al.   Journal of Hematology & Oncology

Multiplexed Engineering and Analysis of Combinatorial Enhancer Activity in Single Cells

(2017) Shiqi Xie et al.   MOLECULAR CELL

Targeting a CAR to the TRAC locus with CRISPR/Cas9 enhances tumour rejection

(2017) Justin Eyquem et al.   NATURE

HLA-E-expressing pluripotent stem cells escape allogeneic responses and lysis by NK cells

(2017) Germán G Gornalusse et al.   NATURE BIOTECHNOLOGY

Synergistic drug combinations for cancer identified in a CRISPR screen for pairwise genetic interactions

(2017) Kyuho Han et al.   NATURE BIOTECHNOLOGY

Pooled CRISPR screening with single-cell transcriptome readout

(2017) Paul Datlinger et al.   NATURE METHODS

In situ programming of leukaemia-specific T cells using synthetic DNA nanocarriers

(2017) Tyrel T. Smith et al.   Nature Nanotechnology

AAV-mediated direct in vivo CRISPR screen identifies functional suppressors in glioblastoma

(2017) Ryan D Chow et al.   NATURE NEUROSCIENCE

T cell-targeting nanoparticles focus delivery of immunotherapy to improve antitumor immunity

(2017) Daniela Schmid et al.   Nature Communications

CRISPR-Cas9 mediated LAG-3 disruption in CAR-T cells

(2017) Yongping Zhang et al.   Frontiers of Medicine

Dissecting Immune Circuits by Linking CRISPR-Pooled Screens with Single-Cell RNA-Seq

(2016) Diego Adhemar Jaitin et al.   CELL

Perturb-Seq: Dissecting Molecular Circuits with Scalable Single-Cell RNA Profiling of Pooled Genetic Screens

(2016) Atray Dixit et al.   CELL

CRISPR-Cas9-mediated multiplex gene editing in CAR-T cells

(2016) Xiaojuan Liu et al.   CELL RESEARCH

Programmable editing of a target base in genomic DNA without double-stranded DNA cleavage

(2016) Alexis C. Komor et al.   NATURE

Optimized sgRNA design to maximize activity and minimize off-target effects of CRISPR-Cas9

(2016) John G Doench et al.   NATURE BIOTECHNOLOGY

Applications of CRISPR technologies in research and beyond

(2016) Rodolphe Barrangou et al.   NATURE BIOTECHNOLOGY

Knock-in of large reporter genes in human cells via CRISPR/Cas9-induced homology-dependent and independent DNA repair

(2016) Xiangjun He et al.   NUCLEIC ACIDS RESEARCH

Genome-wide CRISPR Screen in a Mouse Model of Tumor Growth and Metastasis

(2015) Sidi Chen et al.   CELL

Rapid and highly efficient mammalian cell engineering via Cas9 protein transfection

(2015) Xiquan Liang et al.   JOURNAL OF BIOTECHNOLOGY

Chimeric Antigen Receptor– and TCR-Modified T Cells Enter Main Street and Wall Street

(2015) David M. Barrett et al.   JOURNAL OF IMMUNOLOGY

Genome-scale transcriptional activation by an engineered CRISPR-Cas9 complex

(2015) Silvana Konermann et al.   NATURE

4-1BB costimulation ameliorates T cell exhaustion induced by tonic signaling of chimeric antigen receptors

(2015) Adrienne H Long et al.   NATURE MEDICINE

Generation of knock-in primary human T cells using Cas9 ribonucleoproteins

(2015) Kathrin Schumann et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Spatially resolved, highly multiplexed RNA profiling in single cells

(2015) K. H. Chen et al.   SCIENCE

Identification and characterization of essential genes in the human genome

(2015) T. Wang et al.   SCIENCE

HLA-haploidentical stem cell transplantation after removal of   + T and B cells in children with nonmalignant disorders

(2014) A. Bertaina et al.   BLOOD

Interaction of Monocytes with NK Cells upon Toll-Like Receptor-Induced Expression of the NKG2D Ligand MICA

(2014) M. Kloss et al.   JOURNAL OF IMMUNOLOGY

CAS9 transcriptional activators for target specificity screening and paired nickases for cooperative genome engineering

(2013) Prashant Mali et al.   NATURE BIOTECHNOLOGY

Multiplex Genome Engineering Using CRISPR/Cas Systems

(2013) L. Cong et al.   SCIENCE

Hallmarks of Cancer: The Next Generation

(2011) Douglas Hanahan et al.   CELL

The CRISPR System: Small RNA-Guided Defense in Bacteria and Archaea

(2010) Fedor V. Karginov et al.   MOLECULAR CELL

NK cell-mediated killing of target cells triggers robust antigen-specific T cell-mediated and humoral responses

(2009) P. Krebs et al.   BLOOD

Insertional Transformation of Hematopoietic Cells by Self-inactivating Lentiviral and Gammaretroviral Vectors

(2009) Ute Modlich et al.   MOLECULAR THERAPY